In the setting of combinatory therapy venetoclax plus ibrutinib, a phase II non-randomized trial (NCT02756897) in treatment-naive patients [66] has shown a 3-year progression-free survival (PFS) of 93%, including durable activity in del(17p)/TP53-mutated CLL. This evidence concerns the gene TP53 and B-cell chronic lymphocytic leukemia.